Mast Therapeutics, Inc. (NYSE: MSTX) is a biopharmaceutical company developing therapies for life-threatening diseases. The company’s lead product candidate is MST-188, which has hemorheologic, cytoprotective, and anti-inflammatory properties and is in phase 3 study for the treatment of sickle cell disease in patients. For more information, visit the company’s website at www.masttherapeutics.com.